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Hepatocellular carcinoma (HCC) is an aggressive cancer with
a poor prognosis. The speciﬁc cellular gene alterations responsible
for hepatocarcinogenesis are not well known. Cytokine-induced
antiapoptotic molecule (CIAPIN1), a recently reported antiapop-
totic molecule which plays an essential role in mouse deﬁnitive
hematopoiesis, is considered a downstream effecter of the recep-
tor tyrosine kinase–Ras signaling pathway. However, the exact
function of this gene in tumors is not clear. In this study, we
reported that CIAPIN1 is highly expressed in HCC as com-
pared with non-tumor hepatic tissue (P < 0.05). We employed
adenovirus-mediated RNA interference technique to knock down
CIAPIN1 expression in HCC cells and observed its effects on
HCC cell growth in vitro and in vivo. Among the four HCC and
one normal human liver cell lines we analyzed, CIAPIN1 was
highly expressed in HCC cells. Knock down of CIAPIN1 could
inhibit HCC cell proliferation by inhibiting the cell cycle S-phase
entry. Soft agar colony formation assay indicated that the colony-
forming ability of SMMC-7721 cells decreased by  70% after
adenovirus AdH1-small interfering RNA (siRNA)/CIAPIN1 in-
fection. In vivo experiments showed that adenovirus AdH1-
siRNA/CIAPIN1 inhibited the tumorigenicity of SMMC-7721
cells and signiﬁcantly suppressed tumor growth when injected
directly into tumors. These results suggest that knock down of
CIAPIN1 by adenovirus-delivered siRNA may be a potential
therapeutic strategy for treatment of HCC in which CIAPIN1 is
overexpressed.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer of
men and 11th one of women worldwide, especially in several areas of
Asia and Africa. There were 600 000 estimated new cases annually
and almost as many deaths (1). Despite advances in therapy for HCC
such as recent modiﬁcations in chemotherapy and modern surgical
innovations, overall patient outcome has not substantially improved.
The majority of patients with HCC have inoperable disease with very
poor prognosis (2–4). The 5 year survival rate is limited to 25–39%
after surgery (5) and much lower elsewhere (6,7). Long-term survival
is uncommon because of the frequent presence of recurrence, metas-
tasis or the development of new primaries (8,9). Current adjuvant or
palliative treatment modalities have not been conclusively shown to
prolong survival in HCC (10). Although much is known about the
development and causes of HCC (11,12), no effective therapy has
been found for the vast majority of HCC patients. Therefore, novel
approaches to treat liver cancers are needed (12). For example, po-
tential novel gene and immunotherapeutic strategies for HCC are
worthy of study (13,14).
CIAPIN1, a novel antiapoptotic molecule, which does notshow any
homology to known apoptosis regulatory molecules such as Bcl-2
family, caspase family or signal transduction molecules, is proven
to be a mediator of the RAS signaling pathway and plays a vitally
important role in fetal liver (FL) hematopoiesis (15). Microarray
analysis revealed reduced expression of Bcl-xL and Jak2 in FL of
CIAPIN1 null mice, suggesting that CIAPIN1 might exert its function
by upregulating the expression of Bcl-xL and Jak2. In addition, mouse
CIAPIN1 protects Ba/F3 cells against etoposide, c radiationand staur-
oporine in vitro (15). Our previous studies demonstrated that CIA-
PIN1 confers multidrug resistance in gastric cancer cells possibly
by upregulating multidrug resistance gene-1 and multidrug-related
protein-1 expression (16). Furthermore, CIAPIN1 was found to act
as an antiapoptotic molecule invivo because CIAPIN1 /  mice die in
late gestation due to defective deﬁnitive hematopoiesis in the FL;
however, the researchers did not observe the liver defect pertaining
to HCC in micewith these mutant strains (15). Whether both loss and/
or gain of CIAPIN1 function contribute to cancer development re-
mains unclear and warrant further research. Moreover, the prognostic
value of altered CIAPIN1 expression and its use as a potential target
for cancer therapy are completely unknown and the molecular basis
for its effect on cancer biology is unclear.
In this study, we established that CIAPIN1 is highly expressed in
HCC tissues and HCC cell lines. Then, we employed the newly de-
veloped adenovirus-delivered small interfering RNA (siRNA) tech-
nique (17) to study the effects of knock down of CIAPIN1 on HCC
cell growth in vitro and in vivo.
Materials and methods
Tissue samples, cell lines and cell culture conditions
Forty-four HCC and adjacent benign liver (distant from tumor/cirrhosis
1.5 cm) samples were obtained from patients who underwent surgical treat-
ment for HCC at the Department of Hepatobiliary Surgery in Xijing hospital,
Xi’an, China. Tissue samples were obtained intraoperatively from tumors and
tissues during liver resection for HCC in 46 patients at the Singapore General
Hospital. All samples were obtained from patients who gave informed consent
to use excess pathological specimens for research purposes only. Specimens
were frozen in liquid nitrogen and stored until use. The protocols used in the
study were approved by the Hospital’s Protection of Human Subjects
Committee. BEL7402, SMMC-7721, HepG2, HHCC and Chang liver (trans-
formed liver cell line) were preserved in our institute and HEK293 (Ad5
E1-transformed human embryo kidney cell line) cells were purchased from
American Type Culture Collection (Manassas, VA). All the cell lines were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal
calf serum (Sigma Chemical Co., St Louis, MO) and maintained at 37Ci n
a humidiﬁed chamber with 5% CO2.
Recombinant adenovirus generation
The complementary DNA sequence of CIAPIN1 was obtained from GenBank
(accession no. BC024196). The potential target sequences for RNA interfer-
ence (RNAi) were scanned with the siRNA Target Finder and Design
Tool available at the Ambion Web site. The target sequence selected,
5#-CCAAAGTCAGCTTGTGGAATTCAAGAGATTCCACAAGCTGACTTT-
GGTTTTT-3# (sense), corresponds to a region 349–369 bp after the CIAPIN1
start codon. The target sequence was subcloned into pShuttle-H1 according
to the method of Shen et al. (17). The pShuttle-H1-siRNA/CIAPIN1 was
Abbreviations: FL, fetal liver; GFP, green ﬂuorescent protein; HCC, hepato-
cellular carcinoma; mRNA, messenger RNA; MOI, multiplicity of infection;
PCR, polymerase chain reaction; PBS, phosphate-buffered saline; RNAi, RNA
interference; siRNA, small interfering RNA.
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ation, ampliﬁcation and titer were done according to the simpliﬁed system
described by He et al. (18). Viral particles were puriﬁed by cesium chloride
density gradient centrifugation.
Adenovirus infection
Cells were incubated with adenovirus in a small volume of serum-free medium
at 37C. After adsorption for 4 h, fresh complete growth medium was added
and cells were placed in the incubator for additional time as indicated for the
following experiments. To acquire the equal infection efﬁciency in different
HCC cell lines, the adenovirus 5 (the same virus type as in the virus-mediated
RNAi system) packaging of green ﬂuorescent protein (GFP) (Ad5-GFP; Stra-
tagene,La Jolla,CA)wasinfectedintofourHCCcell linesand Changliver and
showed the same as up to 90% infection efﬁciency in BEL7402, HepG2 and
HHCC, and Chang liver cells at a multiplicity of infection (MOI) of 20, in
SMMC-7721 cells at a MOI of 30, at which concentrations no virus toxicity
effect on cells was found. Thus, the following experiments were performed
using viruses at such MOIs except for special indications.
Reverse transcription–PCR analysis
Total RNA was extracted using TRIZOL reagent (Invitrogen, Carsbad, CA)
according to the protocol of the manufacturer. Two micrograms of RNA was
subjected to reverse transcription. The polymerase chain reaction (PCR) pri-
mers used were as follows: for CIAPIN1, 5#-CGG AAT TCATGG CAG ATT
TTG GGA TCT C-3# (forward), 5#-GGT CGA CCT AGG CAT CAA GAT
TGC TAT C-3# (reverse) and for b-actin, 5#-ATG ATATCG CCG CGC TCG
TC-3# (forward), 5#-CGC TCG GTG AGG ATC TTC A-3# (reverse). PCR
products were separated on a 1% agarose gel, visualized and photographed
under ultra violet light.
Western blot analysis
For protein detection, the cell lysates were harvested and analyzed by western
blots. The antibodies used were monoclonal antibodies against CIAPIN1
prepared by our group (19), antipoly adenosine diphosphate ribose poly-
merase (Cell Signaling Technology), anti-cyclinD1, anti-p27, anti-Bcl-2,
anti-Bax, anti-Bcl-xL, (Santa Cruz Biotechnology, Santa Cruz, CA) and
anti-b-actin (Sigma) antibodies. Densitometry analysis of protein levels
was performed by using Scion-Image 4.0.2 software (Scion Corporation,
Frederick, MD).
Cell viability and proliferation
Cell viability was examined by routine 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay 3 days after virus infection at the indicated
MOI. A cell proliferation assay was done by counting cell number. Cells
were plated at a density of 5.0   104 cells/ml in 24-well plates in triplicate
and infected with the virus at the indicated MOIs. Cells were harvested daily
and counted using a hemocytometer.
Colony formation assay and ex vivo tumor inhibition
Asoftagarcolonyformationassaywasusedtoassesstheanchorage-independent
growth ability of cells. Speciﬁcally, SMMC-7721 cells were infected with virus
for24hatanMOIof30.Cellswerethenplatedona0.6%agarosebaseinsix-well
plates (1.0   104 per well) in 1 ml of Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum and 0.3% agarose. Colonies .50 lmw e r e
counted 15 days after plating.
Four days after infection, 3.0   106 infected or mock cells were injected
subcutaneously into male athymic nude mice (4 weeks of age, ﬁve mice
per group; BiKai Co., Shanghai, China). The tumors were monitored with
a caliper every week over a 6 week period after initial cells were injected.
Then, the tumor-bearing mice were killed and the tumors were removed and
weighed.
Cell cycle analysis
Standard ﬂuorescence-activated cell sorter analysis was used to determine the
distribution of cells in cell cycle or apoptosis of the cells. Brieﬂy, the cells were
infected with AdSiCIAPIN1 or AdSiGFP virus for 2–4 days. Adherent cells
then were collected by trypsinization and ﬁxed with 70% ethanol overnight
at 4C. After washing with phosphate-buffered saline (PBS), the cells were
treated with 100 lg/ml RNase A (Roche Diagnostics), 50 lg/ml of propidium
iodide (Sigma) and 0.05% (vol/vol) Triton X-100 and incubated for 45 min at
room temperature. The samples were analyzed using a FACScalibur ﬂow
cytometer (Becton Dickinson, San Jose, CA). The cell cycle distribution
was established by plotting the intensity of the propidium iodide signal,
which reﬂects the cellular DNA content. Apoptotic cells were identiﬁed as
a hypodiploid DNA peak representing cells (sub-G1). Findings from at least
20 000 cells were collected and analyzed with CellQuest software (Becton
Dickinson).
4#,6-Diamidino-2-phenylindole staining
After infection for 4 days, virus-treated and untreated (mock) cells were ﬁxed
with4%paraformaldehyde(wt/vol)in PBS,pH7.4,at roomtemperature for10
min. Then the cells were stained with 4#,6-diamidino-2-phenylindole (Sigma)
at 1 lg/ml in PBS for 2 min, washed with PBS and mounted using PBS:gly-
cerol (3:1, vol/vol). Fluorescence was visualized with an Olympus standard
ﬂuorescence microscope (Olympus, Tokyo, Japan). Normal nuclei were iden-
tiﬁed as non-condensed chromatin dispersed over the entire nucleus. Apoptotic
nuclei were identiﬁed by condensed chromatin, contiguous to the nuclear
membrane, and nuclear fragmentation of condensed chromatin.
HCC xenograft tumor model in nude mice
The SMMC-7721 cells were grown to subconﬂuency in complete medium.
Viable cells (2.0   106 in PBS/100 ll) were injected subcutaneously into
the ﬂanks of 4-week-old nude mice. Two weeks after tumor cell inoculation,
mice were divided randomly into three groups (six mice per group) and were
treated every other day for 10 days by way of multiple-center intratumor in-
jection of 100 ll of AdSiCIAPIN1 or AdSiGFP at 2.0   108 plaque-forming
units per animal or PBS as a control. The tumors were monitored with a caliper
every week over an 8 week period after cell inoculation. Tumor volume for
each mouse was determined (in cubic millimeter) by measuring in two
directions and calculated as tumor volume 5 length   (width)2/2. One week
after the last virus injection, one of the mice in each group was killed and
the xenografted tumors were excised and prepared with a routine patho-
logical procedure. Tumor sections were deparafﬁnized and subjected to
immunohistochemistry analysis as described in the Adenovirus infection and
Immunohistochemistry.
Immunohistochemistry
Tissue samples were ﬁxed in 10% buffered formalin solution and embedded in
parafﬁn. For CIAPIN1 immunostaining, mouse anti-CIAPIN1 monoclonal an-
tibody (16) was used at 1:3000 dilution. The tumor sections were visualized
using a streptavidin peroxidase kit (Beijing Zhongshan Company, Beijing,
China). In situ apoptosis assay was performed with the DeadEnd colorimetric
terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling sys-
tem (Promega, Madison, WI). Apoptotic nuclei were stained dark brown.
Statistical analysis
Each experiment was repeated at least three times. Bands from western blot or
reverse transcription–PCR were quantiﬁed by Quantity One software
(Bio-Rad). Relative protein or messengerRNA (mRNA) levels were calculated
by referring them to the amount of b-actin. The difference between means was
performed with analysis of variance and then a post hoc test. All statistical
analyses were performed using SPSS11.0 software (Chicago, IL). P , 0.05
was considered as statistically signiﬁcant.
Results
CIAPIN1 expression is elevated in majority HCC patient samples and
HCC cell lines
The pathologic data are summarized as follows: concomitant liver
cirrhosis occurred in 17 (39%) of 44 patients and dysplasia within
the cirrhotic liver was diagnosed in 9 (21%) of 44 patients. Sixteen of
44 (36%) HCC samples had a single tumor and 28 of 44 (64%) had
multiple HCC nodules. Satellite formation occurred in 23 (52%) of 44
patients. No patients claimed that they have exposed to benzene hex-
achloro- HCB or afratoxin. Twenty-four of 44 (55%) patients have
infected the hepatitis B virus and/or hepatitis C virus virus before. The
CIAPIN1 expression in the HCC samples with the hepatitis B virus
and/or hepatitis C virus infection was similar to that in the uninfected
Table I. Summary of immunohistochemical analysis of CIAPIN1 in
adjacent benign liver and HCCs
Immunostaining Adjacent
benign liver
HCCs (n 5 44)
Stage I
(n 5 6)
Stage II
(n 5 18)
Stage III
(n 5 9)
Stage IV
(n 5 11)
Negative 26/44 (59.1%) 3/6 (50%) 6/18 (30%) 2/9 (22%) 2/11 (18%)
Weak 12/44 (27.3%) 1/6 (17%) 4/18 (22%) 2/9 (22%) 3/11 (27%)
Strong 6/44 (13.6%) 2/6 (33%) 8/18 (45%) 5/9 (56%) 6/11 (55%)
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1588ones (33 versus 25%, P . 0.05), and we did not ﬁnd any relationship
between the hepatitis B virus and/or hepatitis C virus infection with
the CIAPIN1 expression (P . 0.05).
Here, we investigated the expression of CIAPIN1 in 44 samples of
patients with HCC in China. CIAPIN1 expression was classiﬁed as
negative, weak and strong in 13 (29.6%), 10 (22.7%) and 21 (47.7%)
patients, respectively (Table I). The CIAPIN1 expression in
HCC tumors was signiﬁcantly higher than that in the surrounding
non-tumor liver tissues (P , 0.05, Table I) and the representative
pictures were presented in Figure 1A. To further conﬁrm these obser-
vations, western blot assay was done using four paired human normal
liver tissues and their tumor tissue specimens with known levels of
CIAPIN1 expression by immunohistochemical staining (Figure 1B).
It was clear that the tumor tissue specimens had a drastic increase of
CIAPIN1 expression as compared with the normal liver tissue, which
was consistent with the level of CIAPIN1 protein expression deter-
mined by immunohistochemical staining. Tumorigenesis is associated
with multiple factors and CIAPIN1 overexpression may be an impor-
tant factor in HCC; thus, we hypothesize that knock down of CIA-
PIN1 expression may inhibit the growth of HCC in which CIAPIN1 is
overexpressed.
CIAPIN1 expression in four HCC cell lines was examined to assess
the biological activities by western blot analysis. Chang liver was
used as references for CIAPIN1 expression. Our data indicate that
compared with the Chang liver cells, the expression of CIAPIN1 was
signiﬁcantly increased in all four HCC cell lines (Figure 1C).
Construction of recombinant adenovirus Ad-CIAPIN1 and its effects
on CIAPIN1 expression
We examined the possibility that siRNA expressed from an adenoviral
vector can be used to speciﬁcally inhibit target gene expression in
HCC cells. The adenoviruses packaging of hairpin siRNA targeted
against CIAPIN1 or GFP were used to infect four HCC cell lines. As
shown in Figure 2A, the suppression of CIAPIN1 expression was
detected as early as 48 h after infection, and the suppression was up
to 80% in the cells infected with AdSiCIAPIN1 at 96 h. The inhibitory
effect of the AdSiCIAPIN1 was shown tobe speciﬁc because acontrol
AdSiGFP had no effect on CIAPIN1 expression level. In addition,
AdSiCIAPIN1 did not cause a non-speciﬁc downregulation of gene
expression, as shown by the b-actin control.
To examine the reduction level of target mRNA induced by the
AdSiRNA, a real-time reverse transcription–PCR was performed with
the prepared mRNA from the infected SMMC-7721 cells. As shown
in Figure 2B, AdSiCIAPIN1 caused a dramatic reduction in the level
of CIAPIN1 mRNA whereas the mock or AdSiGFP could not. In
addition, we found a progressive decrease in the mRNA level of
CIAPIN1 in SMMC-7721 cells infected with increasing levels of
the AdSiCIAPIN1 virus (increasing MOI). Thus, the AdSiRNA ex-
pression was correlated with a speciﬁc reduction in the level of target
mRNA. Altogether, these data indicated that the AdSiRNA could
suppress effectively the CIAPIN1 overexpression in HCC cells.
Fig. 1. Immunohistochemical analysis of CIAPIN1 protein expression in
non-tumor liver samples and HCC tissues (44 cases). (A) Representative
photographs were taken at different magniﬁcations ( 200 versus  1000 for
inserts). (a1) HCC tissues  200 magniﬁcation, (a2) HCC tissues  1000
magniﬁcation; (b1) non-tumor liver samples  200 magniﬁcation, (b2) non-
tumor liver samples  1000 magniﬁcation. (B) Western blot analysis of
whole-cell protein extracts prepared from ﬁve paired non-tumorliver(N) and
HCC (T) specimens. The level of CIAPIN1 protein expression was
signiﬁcantly higher in tumor tissue than in normal tissue. (C) CIAPIN1
protein expression is drastically increased in HCC cells compared with the
normal human liver cells, Chang liver, determined by western blot analysis.
b-actin expression levels were used as internal controls.
Fig. 2. Adenovirus packaging of vectors capable of producing short hairpin
RNA-targeting CIAPIN1 was constructed and proved to be speciﬁc and
potent in silencing CIAPIN1 expression in four HCC cell lines. (A) Indicated
cells were infected with AdSiGFP (control) or AdSiCIAPIN1. Cell lysates
were harvested at 48 or 96 h after infection and detected by anti-CIAPIN1
and anti-b-actin antibodies. (B) Real-time reverse transcription–PCR of
CIAPIN1 mRNA from SMMC-7721 cells harvested 2 days after infection at
the indicated MOIs showed a dose-dependent decrease in mRNA levels. At
an MOI of 30, the AdSiCIAPIN1 suppresses the expression of CIAPIN1
mRNA by up to 80% compared with the mock group.
CIAPIN1 inhibits tumorigenesis of HCC
1589Inhibition of cell growth and S-phase entry in HCC cells by depletion
of CIAPIN1
We ﬁrst tested the effect of AdSiCIAPIN1 on the cell viability of
BEL7402, SMMC-7721, HepG2 and HHCC in cell culture. Chang
liver infected with adenovirus at an MOI of 20 was taken as a negative
control. As shown in Figure 3A, after virus infection, AdSiCIAPIN1
signiﬁcantly inhibited cell growth of all four HCC cell lines as com-
pared with AdSiGFP or mock treatment. The difference was more
pronounced after day 3, a time at which essentially all the cells estab-
lished cell–cell contacts. In contrast, we did not observe any effect of
AdSiCIAPIN1 on the cell viability of Chang liver. The inhibitory
effect on SMMC-7721 cell growth also was conﬁrmed by colony
formation assay (Figure 3B), suggesting that autonomous growth po-
tential also is decreased. The number of colonies was not increased
when measurements were made at a later time, indicating that this is
not solely a reﬂection of the reduced growth rate. Additionally, the
Fig. 3. Adenovirus-delivered CIAPIN1 siRNA inhibits HCC cell growth, tumorigenesis and S-phase entry. (A) The growth of HCC cells and normal Chang liver
infectedwithadenovirus wasmeasured by 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyltetrazoliumbromide assay. Values weregiven at the indicatedtime pointsas
the mean absorbance with a standard deviation of four wells. (B) Colony formation assay was performed by using SMMC-7721 cells infected with adenovirus for
96 h. The cells without any infection (mock) were used as control. The data were the averages from three independent triplicate experiments.  P , 0.05 relative to
the mock group.(C) Ex vivo assay for the tumor suppression effect of AdSiCIAPIN1.SMMC-7721 cells were infectedwith adenoviruses or untreatedcells (mock)
in culture plates for 96 h. Then viable cells (3.0   106) were injected subcutaneously into the dorsal ﬂanks of ﬁve mice in each group. Photographs of
a representative mouse in each group are shown. (D) Quantitation of tumor volume shown in (C). Tumor formation was scored weekly. Data were expressed as
means ± standard deviation (n 5 5). (E) AdSiCIAPIN1 decreased S-phase population in HCC cells after infection for 96 h. The S-phase population in the
indicatedcells was determined by ﬂow cytometry and experiments were repeated three times.Error bars: standarddeviation. (F) Cell cycle-related molecules were
determined by western blot analysis. In the western blot analysis, depletion of CIAPIN1 expression could downregulate cyclinD1 but upregulate p27 expression in
SMMC-7721-infected cells.
X.Li et al.
1590suppression effect of AdSiCIAPIN1 on HCC growth was conﬁrmed in
ex vivo assay. We compared the growth of SMMC-7721 cells with
different treatment as tumors in the subcutaneous tissue of male nude
mice. As shown in Figure 3C and D, AdSiCIAPIN1 signiﬁcantly
suppressed tumor growth in mice as compared with control. To de-
terminewhether the cell cycle distribution has changed after depletion
of CIAPIN1 in HCC cells, we performed ﬂow cytometry at 96 h after
virus infection. Our results showed a decreased cell population in the
S phase after AdSiCIAPIN1 infection in all four cell lines compared
with control, as shown in Figure 3E. Taken together, these data in-
dicate that the AdSiRNA-targeting CIAPIN1 exhibited a speciﬁc in-
hibitory effect on the HCC cell growth as well as inhibition of S-phase
entry in HCC cells.
In order to explore the underlying molecular mechanism of CIA-
PIN1 affecting the cell cycle progression, we detected the expression
of cell cycle-related molecules in AdSiCIAPIN1-infected SMMC-
7721 cells, such as cyclinD1, p27, cdk2, cdk4 and p21 by western
blot and found cdk2, cdk4 and p21 were not affected (data not show),
except CyclyinD1 was downregulated and P27 was upregulated (Fig-
ure3F). Therefore, we may infer that G1 to S arrest induced by knock-
ing down CIAPIN1 in HCC cells was at least partly mediated by
downregulation of cyclinD1 and upregulation p27 expression.
Induction of apoptosis in HCC cells by adenovirus-delivered
CIAPIN1 siRNA
Two days after infection of AdSiCIAPIN1, we observed the appear-
ance of some HCC cells being shrunk, rounded up and detached from
plates, suggesting apoptosis had occurred. In contrast, in the Ad-
SiGFP-treated or mockgroup the cells remained attached tothe dishes
and showed normal morphology. To determine whether the depletion
of CIAPIN1 promotes tumor cell death, ﬂow cytometry was per-
formed after infection of adenovirus into four HCC cells. The cells
were analyzed at different time points (48and 96 h) after infection and
signiﬁcant sub-G1 (apoptotic) populations were observed at 96 h
(Figure 4A). We found that variable apoptotic populations existed
in different HCC cells, 11.6% of BEL7402 and 21.3% of HHCC cells
underwent apoptosis in the AdSiCIAPIN1-treated group versus 1.7
and 3.3% in the AdSiGFP-treated group, respectively. Even higher
apoptotic populations were found when SMMC-7721 and HepG2
cells were tested (58.0 and 47.5%, respectively). We conﬁrmed the
apoptosis of HCC cells by 4#,6-diamidino-2-phenylindole staining
(Figure 4B1). To test if apoptosis can be triggered in normal cells
that do not overexpress CIAPIN1, we also infected normal Chang
liver with AdSiRNA. In contrast to HCC cells, we did not observe
signiﬁcant apoptosis of Chang liver at 48 or 96 h after infection
Fig. 4. AdSiRNA-targeting CIAPIN1 induces cell apoptosis. (A) Downregulation of CIAPIN1 promoted apoptosis of the four indicated HCC cell lines. Ninety-
six hours after the virus infection, the adherent cells were collected by trypsinization and determined by ﬂow cytometry. Three individual experiments were
performed, and the cell distribution in the cell cycle was determined by standard ﬂuorescence-activated cell sorter analysis. The cell population in sub-G1 was
shown. The x-axis and y-axis represent DNA content and the cell number, respectively. (B1)4 #,6-Diamidino-2-phenylindole staining showed the apoptotic cells in
HCC cells infected with AdSiCIAPIN1 for 96 h, whereas this apoptosis cannot be seen in normal Chang liver being infected. The arrows indicate the blue color in
apoptotic nuclei with condensed chromatin or nuclear membrane contiguousness morphology. (B2) Apoptosis cell numbers were counted in 100 cells under
ﬂuorescent microscopy, and results were representative of three independent experiments. (C) Western blot analysis of Bcl-2 family mediators of apoptosis
showed that depletion of CIAPIN1 could downregulate Bcl-2 and Bcl-XL and upregulate Bax in AdSiCIAPIN1-transduced cells, suggesting that the apoptotic
effect of CIAPIN1 could be partly mediated by the Bcl-2 family.
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1591(Figure 4B1). Better quantitation of apoptosis has been shown
in Figure 4B2, which was similar to the ﬂow cytometer results shown
in Figure 4A. These data together suggested that depletion of
CIAPIN1 speciﬁcally triggered apoptosis ofCIAPIN1-overexpressing
HCC cells.
Furthermore, analysis of Bcl-2 family mediators of apoptosis, such
as Bcl-2, Bax and Bcl-XL, showed that depletion of CIAPIN1 could
downregulate Bcl-2, Bcl-XL and upregulate Bax in AdSiCIAPIN1-
transduced cells, suggesting that the apoptotic effect of CIAPIN1
could be partly mediated by the Bcl-2 family (Figure 4D).
Suppression of established tumor growth in nude mice by use
of AdSiCIAPIN1
To determine whether the adenovirus-delivered CIAPIN1 siRNA
could serve as a therapeutic agent against HCC tumor formation,
we established a tumor model in nude mice bearing SMMC-7721
xenografts. Two weeks after inoculation of SMMC-7721, AdSiCIA-
PIN1, AdSiGFP or PBS was administered locally by way of multiple-
center intratumor injection. This kind of treatment causes infection of
.90% of tumor cells, which was conﬁrmed by the injection of Ad5-
GFP as a control. After treatment with AdSiCIAPIN1, the tumor
growth obviously was inhibited compared with the AdSiGFP or
PBS animal group (Figure 5A). To investigate the mechanism of
AdSiCIAPIN1-induced inhibition of tumor growth, tumor specimens
were obtainedfrom tumor-bearinganimals after death. The specimens
were subjected to the in situ apoptosis terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling assay. As shown in
Figure 5B, treatment with AdSiCIAPIN1 dramatically induced apo-
ptotic cell death inside the tumors, whereas treatment with AdSiGFP
or PBS did not cause any tumor cell apoptosis. Taken together, these
data indicate that targeting CIAPIN1 by AdSiRNA can exert a strong
antitumor effect in vivo on HCC and that AdSiCIAPIN1 inhibits
tumor growth by inducing apoptosis of CIAPIN1-overexpressing
tumor cells.
Discussion
HCC is the fourth most common cause of death from cancer and
China alone accounts for 53% of all liver cancer deaths worldwide
(20). However, even among patients detected earlier, there are very
few candidates for surgery because they generally lack a hepatic re-
serve as a result of the coexisting advanced cirrhosis (21). Moreover,
clinical observations have shown that tumor recurrence rates are very
high in patients with HCC who receive medical or surgical treatments.
Thus, new treatment modalities must be pursued. With the expecta-
tion of increasing therapeutic efﬁcacy, gene therapy is being investi-
gated as an effective treatment modality (22,23). Cancer gene
therapies can be broadly classiﬁed into two groups: (i) those that
modify the host responses to a tumor and (ii) those that induce direct
antitumor action by introducing genetic material that directly affects
the cancer cell and halts its growth (24). Replacement therapies in-
volving tumor suppressor genes are the prototypes of gene therapies
with direct antitumor action. CIAPIN1 is a recently reported antia-
poptosis molecule, but its biological function is far from being fully
elucidated.
In this study, we detected that CIAPIN1 expression is elevated in
majority HCC patient samples and HCC cell lines, and consequently,
we hypothesized that overexpression of CIAPIN1 may be associated
with hepatocarcinogenesis and knock down of CIAPIN1 may inhibit
tumorigenic growth of HCC in which CIAPIN1 is overexpressed.
The human adenovirus serotype 5 was used in our system. This is
a replication-defective adenovirus with deletion of E1 and E3 genes,
which render this virus incapable of replication itself (18). Moreover,
this system makes use of the efﬁcient homologous recombination in
HEK293 cells, to produce recombinant adenovirus by a double re-
combination event between cotransfected adenoviral backbone plas-
mid pacAd5 and a shuttle plasmid. Our studies here were designed
to test whether the more advantageous AdSiRNA can be applied to
target HCC cells selectively with overexpression of a recently
reported antiapoptosis gene, CIAPIN1, which is overexpressed in a
higher percentage of HCC patients.
Our results show that AdSiRNA can downregulate CIAPIN1 ex-
pression effectively by up to 80% in HCC cells with great speciﬁcity,
indicating the potency of adenovirus-based RNAi as an effective
strategy for cancer therapy. Also, the blockage of proliferation and
induction of apoptosis in HCC cells and the tumor suppression effect
in nude mice additionally support the effectiveness of this treatment.
There is no induced apoptosis observed in normal Chang liver, which
is absent from CIAPIN1 expression, and this speciﬁcity should in-
crease the therapeutic index of RNAi-based therapies.
After cells were treated with AdSiCIAPIN1 for 96 h, we observed
a signiﬁcant decrease of S-phase population in all tested HCC cells.
This blockage of S-phase entry combined with the enhanced cyclinD1
Fig. 5. Local injection of adenovirus-delivered CIAPIN1 siRNA suppresses
the established tumor growth in nude mice. (A) Two weeks after
subcutaneous inoculation of SMMC-7721 cells, three groups of nude mice
were treated every other day for 10 days by intratumor injection of
AdSiCIAPIN1 or AdSiGFP at 2.0   108 plaque-forming units per animal or
mock as a control (arrow). Representative photographs of a mouse in each
group 6 weeks later are shown. (B) Quantitation of tumor volume shown in
(A). The tumor size was measured and the tumor volume was calculated
weekly. Data are presented as mean ± standard deviation (n 5 6). Error bars:
standard deviation. (C) In situ terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling apoptosis analysis of tumor sections
derived from mice receiving different treatments. The apoptotic nuclei were
stained dark brown (original magniﬁcation  200).
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stantiated the effect of CIAPIN1 overexpression on HCC, by regulat-
ing cyclinD1 and P27 to activate expression of genes necessary for
entering into the S phase. Interestingly, in addition to the inhibition of
cell growth, depletion of CIAPIN1 for 96 h triggered apoptosis in all
tested HCC cells. Previous microarray analysis revealed that the ex-
pressions of Bcl-xL and Jak2 were downregulated in FL of CIAPIN1-
null mice (15). In this study, we tested the expression level of three
Bcl-2 family members (Bcl-2, Bcl-xL and Bax) in this CIAPIN1 de-
pletion-triggered apoptosis in HCC cells. We found that depletion of
CIAPIN1 could downregulate Bcl-2 and Bcl-XL and upregulate Bax
in AdSiCIAPIN1-transduced tumor cells, suggesting that Bcl-2 fam-
ily members may contribute partially to the apoptosis of HCC cells
with CIAPIN1 depletion. Because the precise molecular mechanism
for the CIAPIN1 apoptosis signaling pathway is still unclear, there
might be other different mechanisms to trigger apoptosis in different
cell lines depending on the unique genetic context in the individual
lines. In order to explore these differences with the known molecular
differences among the four cell lines. We further explored the role of
p53 in AdSiCIAPIN1-mediated apoptosis. HepG2 and SMMC-7721
cells that contained the wild-type p53 gene were more sensitive to
AdSiCIAPIN1-induced apoptosis than HHCC cells lacking the wild-
type p53 gene and BEL7402 cells containing a mutant p53 gene. The
expression of p53 protein was greatly enhanced in AdSiCIAPIN1-
infected HepG2 and SMMC-7721 cells (supplementary Figure A is
available at Carcinogenesis Online). In contrast, no p53 protein could
be detected in HHCC cells, and no obvious change was detected in
BEL7402 cells.
To explore whether AdSiCIAPIN1-induced cell death in HepG2
was p53 dependent, we generated a HepG2 cell line stably expressing
antisense p53. The reduced p53 expression was conﬁrmed by western
blotting and real-time PCR analysis (supplementary Figure B is avail-
able at Carcinogenesis Online). AdSiCIAPIN1-induced cell death
was signiﬁcantly more attenuated in PsiP53-expressing cells than in
mock or Psilencer3.1-transfected cells (supplementary Figure C is
available at Carcinogenesis Online). However, AdSiCIAPIN1-
induced cell death was not completely abolished. This conﬁrmed
our hypothesis that AdSiCIAPIN1 might induce apoptosis through
different mechanisms in different genetic context cell lines.
In addition to showing the successful use of AdSiRNA in silencing
CIAPIN1 overexpressed in HCC cells, our results also indicate that
CIAPIN1 might serve as a novel promising therapeutic target for
HCCs. CIAPIN1, a newly reported antiapoptosis molecule, is proven
to be a mediator of the RAS signaling pathway and plays a vitally
important role in FL hematopoiesis (15). Previous study indicated that
CIAPIN1 does not show any homology to known apoptosis regulatory
molecules such as Bcl-2 family, caspase family or signal transduction
molecules. Here, we showed that when overexpressed CIAPIN1 was
depleted in HCC, it resulted in multiple antitumor effects in cancer
cells such as inhibition of cell growth and induction of apoptosis.
These results suggest that CIAPIN1 overexpression may be essential
for maintaining cell proliferation as well as cell survival in HCC.
More importantly, we showed the local injection of AdSiRNA for
CIAPIN1 into established tumors in nude mice signiﬁcantly could
inhibit the tumor growth in vivo by inducing apoptosis of HCC cells.
This HCC-targeted therapy is realized by two means. One is the
adoption of local injection delivery of AdSiRNA into the tumor mass
by way of multiple-center injections. The other is to take advantage of
the fact that normal liver cells express very little CIAPIN1. We show
that silencing antiapoptosis molecule CIAPIN1 by AdSiRNA is a po-
tential effective approach to treat HCCs. In conclusion, our results
show that the signiﬁcant downregulation of CIAPIN1 expression in
HCC cells inhibits cell growth in vitro and in vivo and induces the
cancer cell apoptosis. Therefore, our studies suggest that knock down
of CIAPIN1 by adenovirus-delivered siRNA may be a potential
therapeutic strategy in the treatment of HCC in which CIAPIN1 is
overexpressed.
Supplementary material
Supplementary Figures A, B and C can be found at http://carcin.
oxfordjournals.org/
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